Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2008

View Archived Issues

Human somatic cells can be induced into pluripotent stem cells without nuclear transfer

Neuroprotective effects of phosphorylated PRAS40 after spinal cord injury

New PPAR agonists described in recent patent

Novel diagnostic agents disclosed in recent patent from University of California, Oakland

Aastrom initiates patient treatment with stem cell therapy for dilated cardiomyopathy

Targeting the endothelin B receptor may improve the efficacy of tumor immune therapy

Intercell and PATH enter new collaboration for development of malaria vaccine

ActivBiotics extends deadline for sale of company assets until March 2008

Kamada announces completion of phase I studies with aerosolized alpha-1 antitrypsin

DelSite's nasal powder vaccine GelVac to move into phase I clinical trial later this year

Juvaris and Centers for Disease Control and Prevention enter agreement for H5N1 vaccine

Can-Fite expands studies to further investigate efficacy of CF-101 in treating uveitis

MAP completes SPA with FDA for phase III clinical trial of MAP-0004 for migraine

Cerimon initiates phase II/III trials of once-daily diclofenac sodium patch for pain

Novel treatment for spinal cord disorders reported in recent Sia Peptides patent

Denmark approves phase I clinical trials of PlGF antibody TB-403 in cancer

FDA approves ZymoGenetics' Recothrom commercialization

Schering-Plough files NDA for sugammadex in Japan

SGX announces that enrollment has begun in phase I clinical trials of SGX-523 for cancer

EPIX reports revised results from its phase IIa clinical trial of PRX-03140 in AD

XenoPort and GSK report top-line results for XP-13512 in the treatment of RLS

Shire launches Fosrenol in Spain, completing launch roll-out in E.U. markets

Dosing of Tracon's TRC-105 begins in cancer patients enrolled in a phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...